Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00215683 | An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer | completed | Phase 2 / Phase 3 | 137 | Ferring PharmaceuticalsINDUSTRY | 7 | Apr 1, 2015 | clinicaltrials |
| NCT01267266 | Saracatinib in Treating Patients With Prostate Cancer | terminated | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Apr 1, 2015 | clinicaltrials |
| NCT01080352 | Vitamin C as an Anti-cancer Drug | completed | Phase 2 | 31 | Copenhagen University Hospital at HerlevOTHER | 1 | Mar 26, 2015 | clinicaltrials |
| NCT00260611 | Study of Oxaliplatin and Taxotere in Prostate Cancer | completed | Phase 2 | 34 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT01533246 | Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2015 | clinicaltrials |
| NCT00080899 | Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00694291 | Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 1 | Mar 6, 2015 | clinicaltrials |
| NCT01565512 | Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort | withdrawn | Phase 1 / Phase 2 | 0 | Columbia UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00058214 | Perifosine in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT02159690 | A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | withdrawn | Phase 2 | 0 | Kenneth Pienta, MDOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT02344667 | Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. VMAT | unknown | Phase 2 | 40 | Juravinski Cancer CenterOTHER | 0 | Jan 26, 2015 | clinicaltrials |
| NCT00151086 | Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 33 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2015 | clinicaltrials |
| NCT00150995 | Tetrathiomolybdate in Hormone Refractory Prostate Cancer | completed | Phase 2 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00151047 | Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer | completed | Phase 2 | 15 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00151060 | Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate | completed | Phase 2 | 28 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00134355 | Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer | completed | Phase 2 | 5 | University of Michigan Rogel Cancer CenterOTHER | 0 | Jan 19, 2015 | clinicaltrials |
| NCT00913263 | An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate(2-HOF) | completed | Phase 1 / Phase 2 | 24 | Lidds ABINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT02065323 | A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT | withdrawn | Phase 2 | 0 | Oscar Goodman, Jr.OTHER | 1 | Jan 19, 2015 | clinicaltrials |
| NCT02342054 | Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer(SINFRA_PROST) | unknown | Phase 2 | 49 | Hospital de CrucesOTHER | 1 | Jan 19, 2015 | clinicaltrials |
| NCT00706628 | A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer | completed | Phase 2 | 87 | Boehringer IngelheimINDUSTRY | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00666666 | R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01469338 | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | terminated | Phase 2 | 9 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2014 | clinicaltrials |
| NCT01531205 | Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT02283346 | Single Fraction HDR Brachytherapy Plus Hypofractionated EBRT for Low-risk Prostate Cancer: Phase II Trial(AC-P01) | unknown | Phase 2 | 60 | AC Camargo Cancer CenterOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00753220 | Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer(CRITICAL) | terminated | Phase 1 / Phase 2 | 7 | Bostwick LaboratoriesINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00568516 | Phase II Study of ASP3550 in Patients With Prostate Cancer | completed | Phase 2 | 273 | Astellas Pharma IncINDUSTRY | 1 | Oct 29, 2014 | clinicaltrials |
| NCT00918385 | Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer(ARS) | terminated | Phase 2 | 57 | Duke UniversityOTHER | 1 | Oct 29, 2014 | clinicaltrials |
| NCT00751205 | Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) | completed | Phase 2 | 150 | BayerINDUSTRY | 6 | Oct 28, 2014 | clinicaltrials |
| NCT00683475 | A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer | completed | Phase 2 | 138 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 16, 2014 | clinicaltrials |
| NCT01009736 | Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy | completed | Phase 1 / Phase 2 | 60 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 16, 2014 | clinicaltrials |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | Sandy SrinivasOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT02258087 | HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.(PROMOBRA) | unknown | Phase 2 / Phase 3 | 50 | National Institute of Oncology, HungaryOTHER | 1 | Oct 7, 2014 | clinicaltrials |
| NCT00103194 | Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2014 | clinicaltrials |
| NCT01704027 | Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer | terminated | Phase 2 | 28 | Centre Georges Francois LeclercOTHER | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00323882 | Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 28, 2014 | clinicaltrials |
| NCT00385827 | A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) | terminated | Phase 2 | 106 | Centocor, Inc.INDUSTRY | 7 | Aug 20, 2014 | clinicaltrials |
| NCT00476645 | Fulvestrant in Hormone Refractory Prostate Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Aug 5, 2014 | clinicaltrials |
| NCT00672594 | Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy | completed | Phase 2 | 30 | Duke UniversityOTHER | 1 | Aug 4, 2014 | clinicaltrials |
| NCT00004050 | Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer | terminated | Phase 2 | 13 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT00005072 | Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT01424930 | A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 25 | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Jul 25, 2014 | clinicaltrials |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) | withdrawn | Phase 1 / Phase 2 | 0 | Emmanuel Antonarakis, MDOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT00544440 | An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma | completed | Phase 2 | 57 | Janssen Research & Development, LLCINDUSTRY | 1 | Jul 17, 2014 | clinicaltrials |
| NCT00349557 | Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer | completed | Phase 2 | 18 | Benaroya Research InstituteOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT01678313 | Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels | completed | Phase 2 | 140 | Buddhist Tzu Chi General HospitalOTHER | 1 | Jul 15, 2014 | clinicaltrials |
| NCT00278993 | Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy | completed | Phase 2 | 108 | Eisai Inc.INDUSTRY | 1 | Jul 14, 2014 | clinicaltrials |
| NCT00919035 | Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients | completed | Phase 2 | 21 | Oncology Specialists, S.C.OTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00459654 | A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer | completed | Phase 2 | 64 | BayerINDUSTRY | 2 | Jun 25, 2014 | clinicaltrials |
| NCT00337077 | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 121 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2015source: clinicaltrials